Journal article
PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate
BM Paterson, P Roselt, D Denoyer, C Cullinane, D Binns, W Noonan, CM Jeffery, RI Price, JM White, RJ Hicks, PS Donnelly
Dalton Transactions | ROYAL SOC CHEMISTRY | Published : 2014
DOI: 10.1039/c3dt52647j
Abstract
The use of copper radioisotopes in cancer diagnosis and radionuclide therapy is possible using chelators that are capable of binding CuII with sufficient stability in vivo to provide high tumour-to-background contrast. Here we report the design and synthesis of a new bifunctional chelator, 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino) -5-oxopentanoic acid (MeCOSar), that forms copper complexes of exceptional stability by virtue of a cage amine (sarcophagine) ligand and a new conjugate referred to as SarTATE, obtained by the conjugation of MeCOSar to the tumour-targeting peptide Tyr3-octreotate. Radiolabeling of SarTATE with 64CuII, a radioisotope suitable for positron e..
View full abstractGrants
Funding Acknowledgements
This work was partially supported by the Australian Research Council (PSD). Dr Matt Harris (Clarity Pharmaceuticals) is thanked for his support. We thank John A. Karas (Bio21 Institute, University of Melbourne) for guidance on peptide synthesis, and Kerry Ardley and Susan Jackson (Peter MacCallum Division of Molecular Imaging, Melbourne) for their technical contributions. The A427-7 cells were a kind donation from Prof Buck E. Rogers (Washington University, St Louis, MO). Professor Rod Hicks is a recipient of a translational research grant from the Victorian Cancer Agency which supported the in vitro and in vivo testing of this agent.